LOGIN
Tetrahydrocannabinol similar in efficacy & safety as placebo in improving spasticity and pain in MS
October 2018
Tetrahydrocannabinol similar in efficacy & safety as placebo in improving spasticity and pain in MS
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis
Clin Ther. 2018 Sep;40(9):1467-1482. doi: 10.1016/j.clinthera.2017.01.016Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
24 patients diagnosed with progressive multiple sclerosis (MS) experiencing pain and moderate spasticity were randomly assigned to either treatment with an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) or placebo for 4 weeks. Improvements in symptoms were assessed by objective and subjective measures, and the incidence and nature of adverse events were monitored. The results demonstrated n...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.